Evidence map›Paper›PMID 33340024›Full record

ReviewNature reviews. Neurology2021

Improving clinical trial outcomes in amyotrophic lateral sclerosis.

Matthew C Kiernan, Steve Vucic, Kevin Talbot, Christopher J McDermott, Orla Hardiman, Jeremy M Shefner, Ammar Al-Chalabi, William Huynh, Merit Cudkowicz, Paul Talman and 5 more

Registry-linked trialOpen access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nature reviews. Neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06491732 (Electrical Impedance Myography Via the Myolex mScan as an ALS Biomarker), which is not on this map. Cited by 154 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
154citing papers in PubMed, 9 pooled it
14.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06491732 recruitingnot on this mapstarted 2025, after this paper: background citation

Electrical Impedance Myography Via the Myolex mScan as an ALS Biomarker

TypeobservationalSponsorBeth Israel Deaconess Medical CenterRan2025 to 2027Enrolled80ConditionsAmyotrophic Lateral SclerosisArmsElectrical Impedance Myography
3 · Its place in the literature

Who cites it

154 citing papers in PubMed, 9 syntheses or guidelines pooled it, 280 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Perampanel for amyotrophic lateral sclerosis: A systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022
    Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Safety and efficacy of dimethyl fumarate in ALS: randomised controlled study.Annals of clinical and translational neurology · 2021
    Trial
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

94 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 5 countries.

Matthew C KiernanBrain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia. matthew.kiernan@sydney.edu.au.ORCID 0000-0001-9054-026X
Steve VucicSydney Medical School Westmead, University of Sydney, Sydney, New South Wales, Australia.
Kevin TalbotNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.ORCID 0000-0001-5490-1697
Christopher J McDermottSheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.ORCID 0000-0002-1269-9053
Orla HardimanAcademic Neurology Unit, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.
Jeremy M ShefnerDepartment of Neurology, Barrow Neurological Institute, University of Arizona College of Medicine Phoenix, Creighton University, Phoenix, AZ, USA.ORCID 0000-0001-5067-5602
Ammar Al-ChalabiKing's College London, Maurice Wohl Clinical Neuroscience Institute, Department of Basic and Clinical Neuroscience, London, UK.ORCID 0000-0002-4924-7712
William HuynhBrain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0002-6504-8107
Merit CudkowiczMassachusetts General Hospital, Boston, MA, USA.
Paul TalmanNeurosciences Department, Barwon Health District, Melbourne, Victoria, Australia.ORCID 0000-0001-9866-9068
Leonard H Van den BergDepartment of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, Netherlands.
Thanuja DharmadasaNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.ORCID 0000-0001-6544-1091
Paul WicksWicks Digital Health, Lichfield, United Kingdom.ORCID 0000-0002-2293-9284
Claire ReillyThe Motor Neurone Disease Association of New Zealand, Auckland, New Zealand.ORCID 0000-0001-5602-814X
Martin R TurnerNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.ORCID 0000-0003-0267-3180
The University of Sydney · AUUniversity of Oxford · GBBarwon Health · AUCreighton University · USHarvard University · USKing's College London · GBNHS Digital · GBTrinity College Dublin · IEUniversity Medical Center Utrecht · NLUniversity of Sheffield · GB

Funding

Medical Research Council MR/L501529/1Medical Research Council MR/R024804/1Motor Neurone Disease Association ALCHALABI-TALBOT/APR14/926-794Motor Neurone Disease Association TURNER/OCT18/989-797Wellcome Trust
6 · The paper itself

Abstract

Individuals who are diagnosed with amyotrophic lateral sclerosis (ALS) today face the same historically intransigent problem that has existed since the initial description of the disease in the 1860s - a lack of effective therapies. In part, the development of new treatments has been hampered by an imperfect understanding of the biological processes that trigger ALS and promote disease progression. Advances in our understanding of these biological processes, including the causative genetic mutations, and of the influence of environmental factors have deepened our appreciation of disease pathophysiology. The consequent identification of pathogenic targets means that the introduction of effective therapies is becoming a realistic prospect. Progress in precision medicine, including genetically targeted therapies, will undoubtedly change the natural history of ALS. The evolution of clinical trial designs combined with improved methods for patient stratification will facilitate the translation of novel therapies into the clinic. In addition, the refinement of emerging biomarkers of therapeutic benefits is critical to the streamlining of care for individuals. In this Review, we synthesize these developments in ALS and discuss the further developments and refinements needed to accelerate the introduction of effective therapeutic approaches.

Indexed as

Amyotrophic Lateral SclerosisClinical Trials as TopicDisease ProgressionGenetic TherapyHumansImmunomodulating AgentsPrecision MedicineTreatment OutcomeImmunomodulating Agents

Identifiers

PMID33340024
PMCPMC7747476
OpenAlexW3115439136

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.